Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis

Shih Pei Lin; Yi Ting Lee; Shung Haur Yang; Stephanie A. Miller; Shih Hwa Chiou; Mien Chie Hung; Shih Chieh Hung

doi:10.1016/j.canlet.2012.08.036

Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis

Shih Pei Lin
, Yi Ting Lee
, Shung Haur Yang
, Stephanie A. Miller
, Shih Hwa Chiou
, Mien Chie Hung^*
, Shih Chieh Hung

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

Antiangiogenesis is an efficient therapy for eliminating colon cancers, but because of recurrence it remains only palliative. We hypothesized that certain populations of tumor cells resist antiangiogenesis-induced apoptosis and explored the underlying mechanism. We demonstrated that the CD133⁺ population of cells in colon cancer is resistant to anti-angiogenesis therapy. Additionally, we identified an anti-apoptotic signaling pathway responsible for this resistance involving PP2A, p38MAPK, MAPKAPK2, and Hsp27. Thus, this pathway may offer a new avenue to develop target therapy for colorectal cancer.

Original language	English
Pages (from-to)	226-234
Number of pages	9
Journal	Cancer Letters
Volume	328
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2012.08.036
State	Published - 28 Jan 2013

Keywords

Avastin
Cancer stem cells
Colon cancer
Hypoxia
Serum-free

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2012.08.036

Cite this

@article{44b237925bfa4dc198203fe91d9d89f9,

title = "Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis",

abstract = "Antiangiogenesis is an efficient therapy for eliminating colon cancers, but because of recurrence it remains only palliative. We hypothesized that certain populations of tumor cells resist antiangiogenesis-induced apoptosis and explored the underlying mechanism. We demonstrated that the CD133+ population of cells in colon cancer is resistant to anti-angiogenesis therapy. Additionally, we identified an anti-apoptotic signaling pathway responsible for this resistance involving PP2A, p38MAPK, MAPKAPK2, and Hsp27. Thus, this pathway may offer a new avenue to develop target therapy for colorectal cancer.",

keywords = "Avastin, Cancer stem cells, Colon cancer, Hypoxia, Serum-free",

author = "Lin, \{Shih Pei\} and Lee, \{Yi Ting\} and Yang, \{Shung Haur\} and Miller, \{Stephanie A.\} and Chiou, \{Shih Hwa\} and Hung, \{Mien Chie\} and Hung, \{Shih Chieh\}",

note = "Funding Information: This study was supported in part by the National Science Council (97-3111-B-010-001, and 99-3111-B-010-005-), Taipei Veterans General Hospital (V98E1-002), the MD Anderson Cancer Center/China Medical University and Hospital Sister Institution Fund, and the National Yang-Ming University, Ministry of Education. ",

year = "2013",

month = jan,

day = "28",

doi = "10.1016/j.canlet.2012.08.036",

language = "English",

volume = "328",

pages = "226--234",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis

AU - Lin, Shih Pei

AU - Lee, Yi Ting

AU - Yang, Shung Haur

AU - Miller, Stephanie A.

AU - Chiou, Shih Hwa

AU - Hung, Mien Chie

AU - Hung, Shih Chieh

N1 - Funding Information: This study was supported in part by the National Science Council (97-3111-B-010-001, and 99-3111-B-010-005-), Taipei Veterans General Hospital (V98E1-002), the MD Anderson Cancer Center/China Medical University and Hospital Sister Institution Fund, and the National Yang-Ming University, Ministry of Education.

PY - 2013/1/28

Y1 - 2013/1/28

N2 - Antiangiogenesis is an efficient therapy for eliminating colon cancers, but because of recurrence it remains only palliative. We hypothesized that certain populations of tumor cells resist antiangiogenesis-induced apoptosis and explored the underlying mechanism. We demonstrated that the CD133+ population of cells in colon cancer is resistant to anti-angiogenesis therapy. Additionally, we identified an anti-apoptotic signaling pathway responsible for this resistance involving PP2A, p38MAPK, MAPKAPK2, and Hsp27. Thus, this pathway may offer a new avenue to develop target therapy for colorectal cancer.

AB - Antiangiogenesis is an efficient therapy for eliminating colon cancers, but because of recurrence it remains only palliative. We hypothesized that certain populations of tumor cells resist antiangiogenesis-induced apoptosis and explored the underlying mechanism. We demonstrated that the CD133+ population of cells in colon cancer is resistant to anti-angiogenesis therapy. Additionally, we identified an anti-apoptotic signaling pathway responsible for this resistance involving PP2A, p38MAPK, MAPKAPK2, and Hsp27. Thus, this pathway may offer a new avenue to develop target therapy for colorectal cancer.

KW - Avastin

KW - Cancer stem cells

KW - Colon cancer

KW - Hypoxia

KW - Serum-free

UR - https://www.scopus.com/pages/publications/84870329341

U2 - 10.1016/j.canlet.2012.08.036

DO - 10.1016/j.canlet.2012.08.036

M3 - Article

C2 - 23017941

AN - SCOPUS:84870329341

SN - 0304-3835

VL - 328

SP - 226

EP - 234

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this